Mr. Drimer is a successful entrepreneur and business development expert with extensive experience in building management and technical teams. He is the President and CEO of Genesis International Group and has been responsible for more than $500 million in transactions over the last 40-years. Throughout his career, Walter has founded several companies and new ventures in both the for-profit and not-for-profit arenas, including Genesis Search Group, Inc., an executive search company specializing in biotech and health care; Innovation Plus LLC, a smart fastener technology company; and American Private Investors Group, an angels club that matches entrepreneurs with private investors. Walter’s most recent project was the cofounding of Bright Source Energy/LUZ II, a solar energy and clean fuel technology enterprise. Bright Source recently completed its C-round of funding for a total of more than $160 million.

back to top

Mr. Julien Meissonnier, MSc, MBA -- President and Chief Executive Officer
Mr. Meissonnier has 20 years of international business experience in product development, marketing, business development, consulting, financial and general management. He is the founder/manager of R.O.I. Consulting,a business development consulting company. From 2001 to 2008, he was responsible for business development at Evogene, an agro-biotechnology company. The company valuation rose from $1 to over $100 million, went public on the Tel Aviv stock exchange and signed agreements with the global leaders in the field. He also served as CFO of Pigmentan, a specialty chemicals company and as Business Development Manager with Sol-Gel Technologies, a start-up that signed a strategic agreement with Merck KGaA. Prior to immigrating to Israel, he was Global Marketing Manager at Ciba-Geigy/Novartis in Switzerland for a $200 million product line. Early in his career, he held product development and technical customer service positions in France and the USA at Rhone-Poulenc. Mr. Meissonnier holds a Diplôme D'Ingenieur in Physics of Materials from the INSA Lyon, an MSE (Chemical Engineering) from the University of Washington, Seattle, and an MBA from INSEAD, France.

back to top

Dr. Harvey Kasdan, PhD -- Chief Technology Officer
Dr. Kasdan has more than 25 years of experience in medical device development as Director of Product Development, VP R&D and Chief Scientist of IRIS International in California. Dr. Kasdan drove several medical devices from concept to market launches and prepared four 510K FDA submissions that resulted in market launches of products currently generating over $60 million in annual revenues. He is the inventor or co-inventor on 25 patents, and has published over 40 publications. Dr. Kasdan holds BS and MS degrees in Electrical Engineering from MIT and a PhD in Engineering from UCLA.

back to top

Dr. Marvin Slepian, MD -- Chief Medical Officer and Chairman of Scientific Advisory Board
Dr. Slepian is a Professor of Medicine (Cardiology), Director of Interventional Cardiology and Director of the Tissue Engineering Lab at the University of Arizona. Dr. Slepian completed his medicine training at NYU-Bellevue in New York, and his cardiology training at Johns Hopkins where he was a Clinical and Research Fellow. He completed a fellowship in interventional cardiology at the Cleveland Clinic. Dr. Slepian has conducted extensive research, authoring more than 150 publications, development and pre-clinical investigation of novel cardiovascular therapeutic methods and devices, and is the holder of over 25 issued and 41 filed patents. He is an expert in polymeric biomaterials and local drug delivery. Dr. Slepian was instrumental in the formation of SynCardia Systems, maker of the CardioWest^TM Temporary Total Artificial Heart and serves as its Chairman. Dr. Slepian has founded and/or served as acting CEO and Board Member in numerous medical device companies including Focal (NASDAQ-traded, acquired by Genzyme), Endotex, Angiotrax, and Hansen Medical. Dr. Slepian earned his BA in Biochemical Sciences and Science in Human Affairs from Princeton University, his MD from the University of Cincinnati, College of Medicine, and received post-doctoral training at MIT and Washington University.

back to top

Dr. Menashe Rajuan, PhD -- Chief Operating Officer
Dr. Rajuan has a broad background in physics, chemistry and engineering. Recently, he served as COO of HoloOr, a company producing advanced optical lenses based on diffractive optics. He was responsible for new products and processes, process engineering, production, QA & QC, maintenance and safety. He is the founder of R2M, a consulting firm focused on operational and business development with a focus on the transfer of products from R&D to manufacturing.  Previously Dr. Rajuan served as COO of Sol-Gel Technologies, a developer of advanced chemical and pharmaceutical products for cosmetics and drug delivery, Senior R&D Engineer at AVX, a producer of passive electronic components, and Project and Application Manager at Electric Fuel Ltd., a developer of electric vehicles based on zinc-air batteries. He has also worked for Israel's Ministry of Defense. Dr. Rajuan holds a BSc in Physics and Mathematics, an MSc in Physical Chemistry and a PhD in Chemistry (Molecular Dynamics) all from the Hebrew University of Jerusalem. He also holds a diploma in Energy Studies from Tel Aviv University and additional certification in Software Engineering from IBM.

back to top

Dr. Yehoshua Broder, PhD – Chief Biochemist and Laboratory Director

Dr. Broder is a biochemist and molecular biologist with extensive experience with research and development, in particular signal transduction, immunology and molecular interactions. Prior to joining LeukoDx, he was an entrepreneur in drug development. Before that, he was a research scientist at the Israel Institute for Biological Research. Dr. Broder has developed and implemented new biological experiment techniques for elucidation of biochemical pathways as the RRS method and others. He is the author and co-author of numerous papers describing the development of unique experimental methods in these fields. Dr. Broder holds a PhD in molecular genetics from the Technion Institute of Technology in Haifa, Israel, and a BA in chemistry and MSc in biochemistry both from the Hebrew University in Jerusalem, Israel.

back to top